AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...

AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis delves into the company's financials and strategic ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...

Abbvie ( (ABBV) ) has realeased its Q3 earnings. Here is a breakdown of the information Abbvie presented to its investors. AbbVie Inc. is a ...

To keep the lesson grounded in practicality, we'll use ROE to better understand AbbVie Inc. (NYSE ... it measures the profitability of a company in relation to shareholder's equity.

AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis delves into the company's financials and strategic positioning ...

AbbVie Inc. closed $6.12 short of its 52-week high ($207.32), which the company achieved on October 31st. Supported by world-class markets data from Dow Jones and FactSet, and partnering with ...